Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHeruc, G.en
dc.contributor.authorHorowitz, M.en
dc.contributor.authorDeacon, C.en
dc.contributor.authorFeinle-Bisset, C.en
dc.contributor.authorRayner, C.en
dc.contributor.authorLuscombe-Marsh, N.en
dc.contributor.authorLittle, T.en
dc.identifier.citationAmerican Journal of Physiology: Endocrinology and Metabolism, 2014; 307(9):E830-E837en
dc.descriptionPublished 1 November 2014en
dc.description.abstractFat is the most potent stimulus for glucagon-like peptide-1 (GLP-1) secretion. The aims of this study were to determine whether dipeptidyl peptidase IV (DPP-IV) inhibition would enhance plasma active incretin [glucose-dependent insulinotropic polypeptide (GIP), GLP-1] concentrations and modulate the glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to intraduodenal fat infusion. In a double-blind, randomized, placebo-controlled crossover design, 16 healthy lean males received 50 mg vildagliptin (V), or matched placebo (P), before intraduodenal fat infusion (2 kcal/min, 120 min). Blood glucose, plasma insulin, glucagon, active GLP-1, and GIP and peptide YY (PYY)-(3-36) concentrations; resting energy expenditure; and energy intake at a subsequent buffet meal (time = 120-150 min) were quantified. Data are presented as areas under the curve (0-120 min, means ± SE). Vildagliptin decreased glycemia (P: 598 ± 8 vs. V: 573 ± 9 mmol·l⁻¹·min⁻¹, P < 0.05) during intraduodenal lipid. This was associated with increased insulin (P: 15,964 ± 1,193 vs. V: 18,243 ± 1,257 pmol·l⁻¹·min⁻¹, P < 0.05), reduced glucagon (P: 1,008 ± 52 vs. V: 902 ± 46 pmol·l⁻¹·min⁻¹, P < 0.05), enhanced active GLP-1 (P: 294 ± 40 vs. V: 694 ± 78 pmol·l⁻¹·min⁻¹) and GIP (P: 2,748 ± 77 vs. V: 4,256 ± 157 pmol·l⁻¹·min⁻¹), and reduced PYY-(3-36) (P: 9,527 ± 754 vs. V: 4,469 ± 431 pM/min) concentrations compared with placebo (P < 0.05, for all). Vildagliptin increased resting energy expenditure (P: 1,821 ± 54 vs. V: 1,896 ± 65 kcal/day, P < 0.05) without effecting energy intake. Vildagliptin 1) modulates the effects of intraduodenal fat to enhance active GLP-1 and GIP, stimulate insulin, and suppress glucagon, thereby reducing glycemia and 2) increases energy expenditure. These observations suggest that the fat content of a meal, by enhancing GLP-1 and GIP secretion, may contribute to the response to DPP-IV inhibition.en
dc.description.statementofresponsibilityGabriella A. Heruc, Michael Horowitz, Carolyn F. Deacon, Christine Feinle-Bisset, Christopher K. Rayner, Natalie Luscombe-Marsh, and Tanya J. Littleen
dc.publisherAmerican Physiological Societyen
dc.rightsCopyright © 2014 the American Physiological Societyen
dc.subjectgastrointestinal hormones; glucose; metabolismen
dc.titleEffects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy malesen
dc.typeJournal articleen
pubs.library.collectionMedicine publicationsen
dc.identifier.orcidHeruc, G. [0000-0002-6257-6828]en
dc.identifier.orcidHorowitz, M. [0000-0002-0942-0306]en
dc.identifier.orcidFeinle-Bisset, C. [0000-0001-6848-0125]en
dc.identifier.orcidRayner, C. [0000-0002-5527-256X]en
dc.identifier.orcidLuscombe-Marsh, N. [0000-0001-9690-4722]en
dc.identifier.orcidLittle, T. [0000-0001-9814-1036]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.